Although a decrease in disease activity parameters (DAS28 score and CRP levels) was found in patients with RA administered and not administered DXM add-on therapy, a significant reduction in proinflammatory cytokines including TNF-α, IFN-γ, and IL-17A was observed only in those with DXM therapy. Here, IL17A is linked to rheumatoid arthritis.